RSAR: Post-marketing RX Drug Abuse Surveillance Data - IBH Data Source
Forecast New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $250,000 to $700,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Points of contact
-
- CDER Acquisition Liaison cderacquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is procuring post-marketing surveillance data on nonmedical use of prescription and over-the-counter drugs and illegal substance use among individuals entering treatment centers or undergoing substance use disorder assessments, with solicitation release estimated for November 1, 2026 and award anticipated March 1, 2027. The requirement calls for collection and analysis of real-world post-marketing data to support FDA oversight of drug abuse patterns and treatment-seeking populations.
The estimated award value ranges from $250,000 to $700,000 for performance under NAICS 541990 (All Other Professional, Scientific, and Technical Services). Inquiries should be directed to the FDA Acquisition Liaison at cderacquisitions@fda.hhs.gov.
Forecast text
The primary objective of this effort is for the FDA to obtain post-marketing data on NMU of prescription and over-the-counter drugs and use of illegal substances from individuals entering treatment centers or being assessed for treatment of substance use disorders.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast